Cognitive Screening & Referral Workflow Template for Primary Care
A pre-built, customizable clinical workflow template (EHR-agnostic) that embeds validated cognitive screening into routine primary care visits, auto-triggers blood biomarker ordering when red flags appear, and routes positive cases to memory specialists with structured handoff documentation. Practices download, configure for their EHR, and deploy in 2-3 weeks without IT overhead.
25 weeks • 70% confidence
Value Proposition
Eliminates diagnostic bottleneck by embedding early detection into existing primary care workflow; reduces time from symptom recognition to biomarker testing from 8-12 weeks to 1-2 weeks; practices avoid costly specialist referrals for rule-out cases; improves Medicare quality metrics (cognitive impairment screening); template is one-time purchase, no per-test fees.
Target Audience
Small-to-mid primary care practices (10-50 providers) and federally qualified health centers (FQHCs) lacking specialist access; practices using Epic, Cerner, Athena, or paper-based systems
Key Features
- Pre-populated visit template with Montreal Cognitive Assessment (MoCA) or Mini-Cog screening (2-3 minute versions)
- Conditional logic: if screening score abnormal → auto-populate blood biomarker order (phospho-tau, amyloid) with CPT codes
- Referral letter generator: auto-fills patient demographics, screening results, biomarker results (once available) for memory specialist handoff
- And more, with full implementation detail...
Tech Stack
Unlock the full solution
You're seeing a preview. Unlock the complete value proposition, every feature, the full tech stack, the monetization model, and the week-by-week build roadmap, plus a downloadable PDF.
Sign up free to continue3 free solution credits on signup
The build plan is behind the wall
Subscribers get the full monetization model, pricing strategy, and the complete week-by-week roadmap to build this.
Sign up freeOriginal Problem
Delayed Alzheimer's diagnosis leads to missed treatment windows and accelerated cognitive declinePatients and families experience agonizing uncertainty waiting months for definitive Alzheimer's diagnosis through expensive PET/MRI scans and cognitive testing, during which irreversible neurodegeneration progresses unchecked. Current diagnostic pathways are slow, costly, and inaccessible in routine clinical settings, forcing patients into advanced stages before confirmation. A rapid, accurate blood test could enable early intervention when treatments are most effective, but this capability hasn't yet reached everyday clinical practice.
Score: 17.5%